HC21 News

AngioDynamics NanoKnife® System Recognised as One of TIME’s Best Inventions of 2025

DMAC Support •

We are delighted to announce that the AngioDynamics NanoKnife® System has been named one of TIME’s Best Inventions of 2025.

For the past three years, the Aquilant team has proudly distributed this innovative product in the UK, helping to expand access to focal therapy and the NanoKnife irreversible electroporation (IRE) system across more centres nationwide.

This prestigious recognition from TIME is a testament to the dedication of clinicians worldwide who have championed NanoKnife and striven to advance treatment options for patients with prostate cancer.

NanoKnife offers a safe, effective, non-thermal ablation solution for treating prostate cancer – targeting tumours whilst preserving surrounding structures, which helps maintain sexual function and urinary continence.

Congratulations to AngioDynamics on this outstanding achievement!

To read more, visit TIME’s website.

HC21 HC21 News Newsletter Quality
Related News
HC21 News

Highlights from the first Paediatric Networking Study Day

The first Paediatric Networking Study Day took place at Edgbaston Cricket Ground in Birmingham, bringing together paediatric theatre professionals for a day of practical learning and open discussion.

HC21 News
HC21 News

Xograph Showcases the Future of Dental Imaging at Snetterton

Xograph Healthcare, part of HC21 UK, was delighted to join the British Superbike Championship at Snetterton alongside colleagues from Planmeca, bringing the latest developments in dental and maxillofacial imaging to visitors.

HC21 News
HC21 News

Innovation in Focus: NanoKnife IRE at King’s College Hospital

Dr Praveen Peddu of King’s College Hospital NHS Foundation Trust has shared his insights into the use of NanoKnife irreversible electroporation (IRE) technology from AngioDynamics International and its expanding application in cancer treatment.

HC21 News
Choose Your Region

This helps us show the right products, services, and contact details.